References
- Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 2003;61:37–49
- AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: diagnosis and treatment recommendations. J Urol 2003;170: 530–47
- Djavan B, Chapple C, Milani S, Marberger M. State of the art on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology 2004;64:1081–8
- Wilde MI, McTavish D. Tamsulosin. A review of its pharmacological properties and therapeutic potential in the management of symptomatic benign prostatic hyperplasia. Drugs 1996;52:883–98
- Dunn CJ, Matheson A, Faulds DM. Tamsulosin: a review of its pharmacology and therapeutic efficacy in the management of lower urinary tract symptoms. Drugs Aging 2002;19:135–61
- Michel MC, Korstanje C, Krauwinkel W, Kuipers M. The pharmacokinetic profile of tamsulosin oral controlled absorption system (OCAS). Eur Urol Suppl 2005;4:15–24
- Sako K, Nakashima H, Sawada T, Fukui M. Relationship between gelation rate of controlled-release acetaminophen tablets containing polyethylene oxide and colonic drug release in dogs. Pharm Res 1996;13:594–8
- Lyseng-Williamson KA, Jarvis B, Wagstaff AJ. Tamsulosin: an update of its role in the management of lower urinary tract symptoms. Drugs 2002;62:135–67
- Michel MC, Korstanje C, Krauwinkel W, et al. Cardiovascular safety of the oral controlled absorption system (OCAS) formulation of tamsulosin compared to the modified release (MR) formulation. Eur Urol Suppl 2005;4:53–60
- Fix JA, Sako K, Sawada T. Controlled-release oral delivery systems. In Park K, Mrsny RJ eds., Controlled drug delivery: designed technologies for the future, Chapt 2. Oxford: Oxford University Press, 2000;14–24
- Chapple CR, Lorenz J, Mortensen R, et al. Tamsulosin Oral Controlled Absorption System (OCAS) in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH): efficacy and tolerability in a phase 2b dose–response study. Eur Urol Suppl 2005;4:25–32
- Chapple CR, Al-Shukri SH, Gattegno B, et al. Tamsulosin Oral Controlled Absorption System (OCAS) in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH): efficacy and tolerability in a placebo and active comparator controlled phase 3a study. Eur Urol Suppl 2005;4:33–44
- Djavan B, Milani S, Davies J, Bolodeoku J. The impact of tamsulosin oral controlled absorption system (OCAS) on nocturia and the quality of sleep: preliminary results of a pilot study. Eur Urol Suppl 2005;4:61–8
- Wilding I. Bioequivalence testing for locally acting gastrointestinal products: what role for gamma scintigraphy? J Clin Pharmacol 2002;42:1200–10
- Wilding IR, Behrens C, Tardif SJ, et al. Combined scintigraphic and pharmacokinetic investigation of enteric-coated mesalazine micropellets in healthy subjects. Aliment Pharmacol Ther 2003;17:1153–62
- Michel MC, Korstanje C, Krauwinkel W, et al. Comparison of vascular α1-adrenoceptor antagonism of tamsulosin in oral controlled absorption system (OCAS) and modified release (MR) formulations. Eur Urol Suppl 2005;4:45–52
- Michel MC, Chapple CR. Comparison of the cardiovascular effects of tamsulosin Oral Controlled Absorption System (OCAS) and alfuzosin prolonged release (XL). Eur Urol 2006;49:501–9